Aptinyx
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Aptinyx sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
Aptinyx: 8 sponsored US clinical trials, none currently recruiting.
Aptinyx sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Mild Dementia, with 1 trials.
Upper-quartile sponsor footprint
Aptinyx sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
8 total, page 1 of 1
NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)
NCT04148391
Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD
NCT05181995
Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia
NCT04147858
Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN)
NCT04146896
Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder
NCT04044664
Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia
NCT03249103
Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
NCT03219320
Safety, Tolerability, PK of Oral NYX-2925 in Healthy Volunteers
NCT02834741
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 7 |
Therapeutic Areas
How the Aptinyx early-phase archive is shaped
8 indexed studies, none listed as recruiting (0% open); 6 completed (75%).
Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).
Top condition: Mild Dementia (1 trial), 3 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Aptinyx: archived-pipeline peers nationwide
Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Aptinyx sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 archived trials
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Aptinyx page
8 registered trials is a research-attention snapshot, not an endorsement of Aptinyx or any single study.
- None of Aptinyx's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Mild Dementia is the condition Aptinyx studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Mild Dementia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Aptinyx pipeline card: 8 registered trials from official public datasets.Report a data error.